By 2010 the World's Cancer Market is Expected to Reach Sales Greater Than US$60 Billion.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37787) has announced the addition of the Espicom Business Intelligence Ltd report: New Drug Futures: Cancer Chapter to their offering.

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the cancer sector. The report includes unique sales forecasts by major product.

In 2005, we estimate the global anticancer market was worth over US$42 billion (+12.6% YoY) accounting for 7% of global pharmaceutical sales (US$600 billion). Global sales included the sale of cytotoxics, innovative therapies, anti-hormonals plus supportive care (such as anti-emetics). This final segment accounted for nearly half of global sales.

By 2010, the global cancer market is expected to generate sales in excess of US$60 billion due to growth in the sales of existing innovative products and the launch of nearly 60 new products which will account for around 30% of total drug launches. These will offset the decline in sales of cytotoxics and anti-hormonals, which face generic sales erosion, and the uptake of newer products in preference to these older agents.

Cancer is the second most common cause of mortality in the developed world and accounts for around 12.5% of all deaths worldwide. By 2020, it is predicted that the number of new cases of cancer diagnosed will rise to 16 million per annum from 11 million in 2002, with cancer-related deaths reaching 10 million each year versus 6.7 million in 2002. Excluding non-melanoma skin cancers, lung cancer is the most common cancer worldwide with breast cancer being the second most prevalent.

There are several new products that, over the next five years, will change the dynamics within the cancer market. These include, among others:

-The launch of new biologics for colorectal cancer (Panitumumab - Amgen/Abgenix) and advanced melanoma (Ticilimumab -Pfizer/Abgenix).

-The treatment of highly prevalent cancers such as breast, NSCLC and colorectal with a new first-line therapy for breast cancer, lapatinib (GSK), a third-generation oral platinum based therapy, Telcyta (Telik) and an interesting angiogenic kinase inhibitor, vatalanib for the treatment of advanced colorectal cancer from Novartis and Schering AG.

-A new generation of prostate cancer drugs for hormone refractory patients such as Acapodene (GTx), satraplatin (Spectrum Pharmaceutical/ GPC Biotech) and ixabepilone (BMS).

Answering key business questions

- Will GPC/Spectrum Pharmaceuticals be able to fight off generic and new product competition to realise estimated peak sales of US$788 for satraplatin?

- Amgen/Abgenix panitumumab's beneficial dosing regime and tolerability profile will revolutionise the treatment of colorectal cancer. Estimated sales peak at US$1015 million in 2012, but what other cancer might it be indicated for?

Companies and Drugs Mentioned

- Acapodene (GT x)

- AP23573 (ARIAD Pharmaceuticals)

- Dasatinib (Bristol-Myers Squibb)

- Ixabepilone (Bristol-Myers Squibb)

- Lapatinib (GlaxoSmithKline)

- Nexavar (Onyx Pharmaceuticals/Bayer)

- Panitumumab(Amgen/Abgenix)

- Revlimid (Celgene)

- Satraplatin(GPC Biotech/Spectrum Pharmaceutical)

- Sutent (Pfizer)

- Telcyta (Telik)

- Ticilimumab (Pfizer/Amgen)

- Vatalanib (Novartis/Schering)

For more information visit http://www.researchandmarkets.com/reports/c37787